RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non–small cell lung cancer
Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …
Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY
M Nishio, T Seto, M Reck, EB Garon, CH Chiu… - Cancer …, 2020 - Wiley Online Library
In the global phase III RELAY study, ramucirumab plus erlotinib (RAM+ ERL) demonstrated
superior progression‐free survival (PFS) to placebo plus erlotinib (PL+ ERL) in untreated …
superior progression‐free survival (PFS) to placebo plus erlotinib (PL+ ERL) in untreated …
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated …
K Nakagawa, EB Garon, T Seto, M Nishio, S Ponce Aix… - 2019 - ascopubs.org
9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
[HTML][HTML] RELAY, ramucirumab plus erlotinib (RAM+ ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung Cancer, 2023 - Elsevier
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung cancer, 2018 - Elsevier
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
K Nakagawa, EB Garon, T Seto, M Nishio… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
[HTML][HTML] Overall treatment strategy for patients with metastatic NSCLC with activating EGFR mutations
H Hayashi, E Nadal, JE Gray, A Ardizzoni, N Caria… - Clinical lung cancer, 2022 - Elsevier
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are
standard of care in the first-line (1L) setting for patients with metastatic non–small cell lung …
standard of care in the first-line (1L) setting for patients with metastatic non–small cell lung …
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors
S Rossi, L Toschi, G Finocchiaro, V Di Noia… - Clinical Lung Cancer, 2019 - Elsevier
Background Common epidermal growth factor receptor (EGFR) mutations in non–small-cell
lung cancer (NSCLC) predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), with exon …
lung cancer (NSCLC) predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), with exon …
Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non–small cell lung …
N Haratake, H Hayashi, M Shimokawa, Y Nakano… - Clinical lung cancer, 2022 - Elsevier
Introduction Osimertinib is a standard first-line treatment for non–small cell lung cancer
(NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR) …
(NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR) …
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Purpose: We report the final analysis of JVDL (NCT02789345), which examined the
combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2 …
combination of the EGFR tyrosine kinase inhibitor (TKI) osimertinib plus the VEGFR2 …